H3 - Tardive Dyskinesia Risk and Management Guidance

A substantial percentage of people receiving prolonged treatment with antipsychotics may develop Tardive Dyskinesia (TD), an involuntary movement disorder characterized by repetitive and uncontrollable movements. Experts believe that some form of TD now affects an estimated 750,000 people in the U.S. alone. Despite the social, emotional, and physical impact it can have on patients, only about 15-25% of people with the disorder are formally diagnosed, and those with this condition and their families often have difficulty with assessment and management. TD imposes a substantial burden on individuals’ physical functioning, mental well-being, and social activities, even in people with self-assessed mild-to-moderate TD symptoms. This session will highlight key factors that increase a person's risk and guidance for management.